Inovio Pharmaceuticals' INO-3107 FDA Review: Upside and Risk at Crossroads

Inovio Pharmaceuticals' INO-3107 is in FDA review for RRP treatment. The outcome will determine upside and risk for the company. If approved, it will be a significant regulatory milestone. However, if not approved, it could negatively impact the company's financial performance. Investors should closely monitor the FDA review and its implications for Inovio's future.